A practical reference on human growth hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
=== Patentability issues === As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals. The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th-century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility. On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v.
=== Construction === The main use of calcium carbonate is in the construction industry, either as a building material, as limestone aggregate for road building, as an ingredient of cement, or as the starting material for the preparation of builders' lime by heating in a kiln. However, because of weathering mainly caused by acid rain, calcium carbonate (in limestone form) is no longer used for building purposes on its own, but only as a raw primary substance for building materials. Calcium carbonate is also used in the purification of iron from iron ore in a blast furnace. The carbonate is calcined in situ to give calcium oxide, which forms a slag with various impurities present, and separates from the purified iron. In the oil industry, calcium carbonate is added to drilling fluids as a formation-bridging and filtercake-sealing agent; it is also a weighting material which increases the density of drilling fluids to control the downhole pressure. Calcium carbonate is added to swimming pools, as a pH corrector for maintaining alkalinity and offsetting the acidic properties of the disinfectant agent. It is also used as a raw material in the refining of sugar from sugar beet; it is calcined in a kiln with anthracite to produce calcium oxide and carbon dioxide. This burnt lime is then slaked in fresh water to produce a calcium hydroxide suspension for the precipitation of impurities in raw juice during carbonatation. Calcium carbonate in the form of chalk has traditionally been a major component of blackboard chalk.
==== Angiopoietins ==== The angiopoietins, Ang1 and Ang2, are required for the formation of mature blood vessels, as demonstrated by mouse knock out studies. Ang1 and Ang2 are protein growth factors which act by binding their receptors, Tie-1 and Tie-2; while this is somewhat controversial, it seems that cell signals are transmitted mostly by Tie-2; though some papers show physiologic signaling via Tie-1 as well. These receptors are tyrosine kinases. Thus, they can initiate cell signaling when ligand binding causes a dimerization that initiates phosphorylation on key tyrosines.
Sources: en.wikipedia.org
=== Delivery costs === In February 2024, Panera settled a class-action lawsuit for $2 million, which accused the company a year beforehand of misleading customers from 2020 to 2021 about its costs for delivery orders. Panera did not admit fault in the settlement.
Local effects: burning or stinging pain, swelling, redness. Severe systemic reactions: swelling of the tongue and throat, difficulty breathing, and shock. Development of optic neuritis and atrophy. Atrial fibrillation, cerebral infarction, acute myocardial infarction, Fisher's syndrome, acute inflammatory polyradiculopathy (Guillain–Barré syndrome), claw hand (through a central action of apamin on the spinal cord and a peripheral action in the form of median and ulnar neuritis, causing spasms of the long flexors in the forearm). Patients poisoned with bee venom can be treated with anti-inflammatory medication, antihistamines and oral prednisolone. Apamin is an element in bee venom. A person can come into contact with apamin through bee venom, so the symptoms that are known are not caused by apamin directly, but by the venom as a whole. Apamin is the only neurotoxin acting purely on the central nervous system. The symptoms of apamin toxicity are not well known, because people are not easily exposed to the toxin alone. Through research about the neurotoxicity of apamin some symptoms were discovered. In mice, the injection of apamin produces convulsions and long-lasting spinal spasticity. Also, it is known that the polysynaptic spinal reflexes are disinhibited in cats. Polysynaptic reflex is a reflex action that transfers an impulse from a sensory neuron to a motor neuron via an interneuron in the spinal cord. In rats, apamin was found to cause tremor and ataxia, as well as dramatic haemorrhagic effects in the lungs.
=== Plastics production === Several widely used polymers contain acrylonitrile as a monomer and therefore incorporate nitrile groups. Pure polyacrylonitrile (PAN) is difficult to process; consequently, during its production, 85 to 99% acrylonitrile is almost always copolymerized with small amounts of other monomers. Copolymers containing 35 to 85% acrylonitrile, together with other monomers such as vinyl acetate and methyl methacrylate, are also employed. Nitrile polymers are among the most important fully synthetic materials for textile fibers, alongside polyesters and polyamidess. These fibers, known as acrylic fibers, are produced on the scale of several million tons per year. In 2000, global production was approximately 2.7 million tons. Acrylic fibers are used in garments (such as socks and sweaters), blankets, carpets, and knitting yarn, among other applications. PAN is also the principal precursor for the production of carbon fiber, which is used as an exceptionally lightweight yet strong material in automotive and aircraft construction. Global production of the monomer acrylonitrile was approximately 3.2 million tons in 1988. Acrylonitrile butadiene rubbers are known as nitrile rubbers and exhibit advantageous properties such as high tensile strength, high abrasion resistance, and resistance to hydrocarbons (oils and fuels). They are therefore used for sealing rings and for oil and fuel hoses.
Sources: en.wikipedia.org
=== Tendon treatment === Several studies have shown a correlation between the administration of bone growth factors and the amelioration of the tendon-to-bone healing. The focus of these studies was primarily on the anterior cruciate ligament (ACL) located in the knee, due to the high number of injuries sustained by athletes. The University of Dammam, King Fahd Hospital in Saudi Arabia was able to show that the addition of SHMSP bone growth factor via powder facilitated the process of tendon-graft healing in rabbits. Comparison of this SHMSP test group to the control group illustrated a higher level of formation and organization within the knee. The Hospital for Special Surgery in New York conducted a similar study, in which a collagen sponge containing bone protein was implanted in the ACL of rabbits. In this case, the bone protein isolated from bovine femurs contained several bone morphogenetic proteins, which are part of an important signaling system that aides in the structure of bones. As with the application of SHMSP, the inclusion of bone protein in the collagen sponge was seen to improve the healing process, when compared to control groups with the sponge alone or no sponge. In a separate study also implemented by the Hospital for Special Surgery as well as the University of California, treatment of the anterior cruciate ligament utilized the recombinant human bone morphogenic protein rhBMP-2 in two phases.
=== West Africa === At least nine Mexican and Colombian drug cartels have established bases in several West African nations, with notable activity in Guinea-Bissau and Sierra Leone, among other places. They have reportedly worked closely with local criminal gangs to carve out a staging area for access to the lucrative European market. The Colombian and Mexican cartels have discovered that it is easier to smuggle large loads into West Africa and then break that up into smaller shipments to Europe – mostly Spain, the United Kingdom and France. Higher demand for cocaine in Western Europe in addition to North American interdiction campaigns has led to dramatically increased trafficking in the region: nearly 50% of all non-U.S. bound cocaine, or about 13% of all global flows, is now smuggled through West Africa.
=== Pharmacokinetics === The naturally occurring native GLP-1 hormone is considered a peptide hormone. It has a half-life of only about two minutes, because the dipeptidyl peptidase-4 (DPP-4) enzyme rapidly breaks it down. As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed daily, weekly, or less often. Many commonly used synthetic GLP-1 agonists are delivered weekly by subcutaneous injection, which is a barrier to their use and reason for discontinuation. Most GLP-1 medications are approved by the FDA and sold as drug-device combination products, which include auto-injecting pens. Self-injected drugs are especially difficult for people with vision or motor difficulties, which commonly accompany type 2 diabetes. Attempts to develop an orally bioavailable GLP-1 agonist, either a modified peptide, as in the case of oral semaglutide, or a small molecule drug, have produced additional drug candidates. Other companies have tested inhaled or transdermal administration. An oral semaglutide pill was approved by the FDA in December 2025 and entered mass production in January 2026.
Unk is sometimes used instead of Xaa, but is less standard. Ter or * (from termination) is used in notation for mutations in proteins when a stop codon occurs. It corresponds to no amino acid at all. In addition, many nonstandard amino acids have a specific code. For example, several peptide drugs, such as Bortezomib and MG132, are artificially synthesized and retain their protecting groups, which have specific codes. Bortezomib is Pyz–Phe–boroLeu, and MG132 is Z–Leu–Leu–Leu–al. To aid in the analysis of protein structure, photo-reactive amino acid analogs are available. These include photoleucine (pLeu) and photomethionine (pMet).
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.